The ATM shelf increase signals ongoing cash needs at a distressed valuation. Traders should expect continued selling pressure as the company draws down this facility. Short interest may already be elevated given the history of dilutive offerings. Watch for any press releases on pipeline catalysts (e.g., Talicia, Movantik, or other GI programs) that could provide a bounce against this overhang, but avoid catching the falling knife until the ATM is exhausted or a non-dilutive financing event occurs.
Price Chart
Executive Summary
RedHill Biopharma updated its ATM sales agreement shelf to allow sale of up to $2,128,000 in ADSs, supplementing prior sales of $49,690. At a $5M market cap and a $0.8786/ADS stock price, the potential 30%+ dilution is materially bearish for existing shareholders, especially given the company's tiny public float and pre-revenue status.
Key Facts
- Registration of up to $2,128,000 in new ADSs under existing ATM Sales Agreement with H.C. Wainwright.
- Each ADS represents 10,000 ordinary shares, creating extreme dilution mechanics.
- Only $49,690 in ADSs had been sold prior to this supplement.
- Public float (non-affiliate market value) is only $6,534,464 as of April 30, 2026.
- Last reported ADS price on June 26, 2026 was $0.8786 — near all-time lows for this micro-cap.
- Company is a pre-revenue / minimal-revenue clinical-stage biopharma with high cash burn risk.
Financial Impact
Up to $2.128M in new equity potentially representing ~33% of current public float, creating severe dilution to existing holders.
Risk Factors
- Continued dilution as company sells new ADSs into weak market conditions.
- Potential Nasdaq delisting if ADS price stays below $1.00 and market cap remains low.
- No guaranteed commercial revenues to offset cash burn — pipeline execution risk is binary.
- Historical trading patterns show large negative moves after similar neutral/caution signals.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 424B5 Filing (Primary) | 0001178913-26-003349 |
| Document: 0001178913-26-003349-index-headers.html | 0001178913-26-003349 |
| Document: 0001178913-26-003349-index.html | 0001178913-26-003349 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 21, 2026 5d ago | 6-K | $0.4550 | awaiting T+60 | — | $0.4230 (−7.03%) |
Oct 19, 2026 7d ago | 6-K | $0.5012 | awaiting T+60 | — | $0.4230 (−15.60%) |
Oct 19, 2026 7d ago | Press Release | $0.5012 | awaiting T+60 | — | $0.4230 (−15.60%) |
Oct 13, 2026 12d ago | 6-K | $0.4862 | awaiting T+60 | — | $0.4230 (+13.00%) |
Oct 13, 2026 12d ago | 424B5 | $0.4862 | awaiting T+60 | — | $0.4230 (+13.00%) |
Oct 7, 2026 19d ago | 6-K | $0.4740 | awaiting T+60 | — | $0.4230 (−10.76%) |
Sep 1, 2026 7w ago | 6-K | $0.8700 | awaiting T+60 | — | $0.4230 (−51.38%) |
Aug 31, 2026 8w ago | 6-K | $0.9000 | awaiting T+60 | — | $0.4230 (−53.00%) |
Aug 7, 2026 11w ago | 6-K | $0.6050 | awaiting T+60 | — | $0.4230 (−30.08%) |
Aug 6, 2026 11w ago | 6-K | $0.5810 | awaiting T+60 | — | $0.4230 (−27.19%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers